Clinical Research Directory
Browse clinical research sites, groups, and studies.
Topical Sulfasalazine and Oral Lichen Planus
Sponsor: Cairo University
Summary
Oral lichen planus (OLP) is a chronic inflammatory disease that affects the mucosal membrane. T-cell mediated damage against the mucosal epithelial cells is implicated in the pathogenesis of OLP, although the exact mechanism is unknown. Sulfasalazine is extensively used in inflammatory bowel disease and is effective on immune-related inflammatory disease such as Crohn's disease, rheumatoid arthritis, and Behcet's disease. In spite of its effectiveness, the anti-inflammatory mechanism is not clearly understood.
Official title: Adjunctive Effect of Topical Sulfasalazine for Oral Lichen Planus Management: A Randomized Clinical Trial
Key Details
Gender
All
Age Range
30 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2023-03-01
Completion Date
2024-10-20
Last Updated
2024-08-01
Healthy Volunteers
No
Interventions
sulfasalazine 500 MG
The patients will use topical corticosteroids in addition to topical sulfasalazine 4 times per day.
corticosteroids
The patients will use topical corticosteroids 4 times per day.
Locations (1)
Faculty of Dentistry, Cairo University
Cairo, Egypt